Company: PRME
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001193125-25-122158
Chunk: 3

Company: Prime Medicine, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 3
---
. In connection with Dr. Reine’s appointment to the Board, the Board determined that Dr. Reine is not independent under the
applicable listing standards of the Nasdaq Stock Market LLC. Accordingly, Dr. Reine was not appointed to serve on any committees of the Board. Dr. Reine will not receive any additional compensation in connection with his service as a
member of the Board.

In connection with Dr. Reine’s appointment as Chief Executive Officer, the Company entered into an Amended and Restated
Employment Agreement (the “Reine Employment Agreement”), effective as of May 19, 2025, pursuant to which the Company has agreed to pay Dr. Reine an annual base salary of $665,000. Dr. Reine is also eligible to earn an annual target
bonus of 60% of his annual base salary. During Dr. Reine’s employment, he will be eligible to participate in the Company’s equity compensation plans and employee benefit plans available to other employees of the Company. Upon the effective
date of the Reine Employment Agreement, the Reine Employment Agreement will fully supersede the Employment Agreement, dated January 17, 2024, by and between the Company and Dr. Reine.

Pursuant to the Reine Employment Agreement, in the event Dr. Reine is terminated by the Company without “Cause” or he resigns for “Good
Reason” (as such terms are defined in the Reine Employment Agreement), in each case subject to the delivery of and compliance with a fully effective separation agreement that shall include, without limitation, a general release of claims,
reaffirmation of applicable restrictive covenants and, in the Company’s discretion, a one year non-competition agreement, Dr. Reine will be entitled to (i) an amount equal to the sum of
(A) twelve (12) months of his then-

current base salary plus (B) 1.0 times his target annual bonus for the then current year, in each case subject to reductions by any amount received by him pursuant to a restrictive covenant
agreement, and (ii) subject to Dr. Reine’s co-payment of premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the
portion of the premium equal to the amount the Company would have paid to provide health insurance had he remained employed by us until the earliest of (A) twelve (12) months following his termination, (B) his eligibility